Market Research Logo

European Market Report for Modern Insulin 2016 - MedCore

European Market Report for Modern Insulin 2016 - MedCore

The European modern insulin market can be segmented by insulin type, yielding three segments: long-acting insulin, rapid-acting insulin and premixed insulin. In 2015, the largest segment in the total modern insulin market was the long-acting insulin segment, which represented nearly 50% of the total market value. Patent expirations and the introduction of new products will lead to higher unit sales growth in this segment, relative to the rapid-acting insulin and premixed insulin segments. Combined with modest appreciation of ASP, it is projected that long-acting insulin will be the fastest growing segment in the total modern insulin market over the forecast period.

Insulin is a hormone that causes glucose uptake from the blood through the cells of the liver, muscle and fat tissue to be stored as glycogen in the liver and muscle. Type 1 diabetics’ immune systems destroy pancreatic beta cells: the only cells that can make insulin. The body therefore fails to produce insulin and cannot naturally convert food into energy. Type 2 diabetics have a resistance to insulin, and cells are not able to use the insulin present in the body. The need for insulin increases to the point that the pancreas can no longer produce it. Insulin is therefore a mode of treating both type 1 and type 2 diabetes.


EXECUTIVE SUMMARY
EUROPEAN MARKET FOR DIABETES MONITORING, TREATMENT AND DRUG DELIVERY
COMPETITIVE ANALYSIS
MARKET TRENDS
MARKET DEVELOPMENTS
MARKETS INCLUDED
KEY REPORT UPDATES
VERSION HISTORY
RESEARCH METHODOLOGY
1.1 RESEARCH SCOPE
1.2 IDATA’S 9-STEP METHODOLOGY
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecast and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring
DISEASE OVERVIEW
2.1 INTRODUCTION
2.1.1 Types of Diabetes
2.1.2 Diabetes Complications
2.1.3 Risk Factors Associated with Type 1 and Type 2 Diabetes
2.1.4 Signs and Symptoms
2.1.5 Diabetes Monitoring
2.1.6 Treatment
2.1.7 Drug Delivery Systems
COUNTRY PROFILES
3.1 INTRODUCTION
3.1.1.1 Population
3.1.1.2 GDP Per Capita
3.1.1.3 Units
3.2 GERMANY
3.3 FRANCE
3.4 UNITED KINGDOM
3.5 ITALY
3.6 SPAIN
3.7 BENELUX
3.8 SCANDINAVIA
3.9 AUSTRIA
3.10 SWITZERLAND
3.11 PORTUGAL
MODERN INSULIN MARKET
4.1 INTRODUCTION
4.1.1 Insulin Types
4.1.1.1 Rapid-Acting Insulin Analogs
4.1.1.2 Regular Human Insulin
4.1.1.3 Intermediate-Acting Insulin Analogs
4.1.1.4 Long-Acting Insulin Analogs
4.1.1.5 Ultra-Long-Acting Insulin Analogs
4.2 MARKET OVERVIEW
4.3 MARKET ANALYSIS AND FORECAST
4.3.1 Total Modern Insulin Market
4.3.2 Long-Acting Insulin Market
4.3.3 Rapid-Acting Insulin Market
4.3.4 Premixed Insulin Market
4.4 DRIVERS AND LIMITERS
4.4.1 Market Drivers
4.4.2 Market Limiters
4.5 COMPETITIVE MARKET SHARE ANALYSIS
ABBREVIATIONS
List of Charts
Chart 1 1: Diabetes Diagnosis, Treatment and Drug Delivery, Europe, 2012 – 2022
Chart 1 2: Diabetes Diagnosis, Treatment and Drug Delivery Market Overview, Europe, 2012 & 2022
Chart 3 1: Country Profile, Germany, 2015
Chart 3 2: Country Profile, France, 2015
Chart 3 3: Country Profile, United Kingdom, 2015
Chart 3 4: Country Profile, Italy, 2015
Chart 3 5: Country Profile, Spain, 2015
Chart 3 6: Country Profile, Benelux, 2015
Chart 3 7: Country Profile, Scandinavia, 2015
Chart 3 8: Country Profile, Austria, 2015
Chart 3 9: Country Profile, Switzerland, 2015
Chart 3 10: Country Profile, Portugal, 2015
Chart 4 1: Total Modern Insulin Market by Segment, Europe, 2015
Chart 4 2: Total Modern Insulin Market Breakdown, Europe, 2015
Chart 4 3: Total Modern Insulin Market Breakdown, Europe, 2022
Chart 4 4: Total Modern Insulin Market, Europe, 2012 – 2022 (€M)
Chart 4 5: Long-Acting Insulin Market, Europe, 2012 – 2022 (€M)
Chart 4 6: Rapid-Acting Insulin Market, Europe, 2012 – 2022 (€M)
Chart 4 7: Premixed Insulin Market, Europe, 2012 – 2022 (€M)
Chart 4 8: Leading Competitors, Insulin Market, Europe, 2015
List of Figures
Figure 1 1: Diabetes Diagnosis, Treatment and Drug Delivery Competitor Market Share Ranking by Segment, Europe, 2015 (1 of 2)
Figure 1 2: Diabetes Diagnosis, Treatment and Drug Delivery Competitor Market Share Ranking by Segment, Europe, 2015 (2 of 2)
Figure 1 3: Companies Researched in this Report, Europe, 2015
Figure 1 4: Factors Impacting the Diabetes Diagnosis, Treatment and Drug Delivery Market by Segment, Europe (1 of 2)
Figure 1 5: Factors Impacting the Diabetes Diagnosis, Treatment and Drug Delivery Market by Segment, Europe (2 of 2)
Figure 1 6: Recent Events in the Diabetes Diagnosis, Treatment and Drug Delivery Market, Europe, 2012 – 2016
Figure 2 1: Major Types of Diabetes and Related Pathologies, Europe, 2015
Figure 2 2: Risk Factors Associated with Type 1 and Type 2 Diabetes, Europe, 2015
Figure 2 3: Signs and Symptoms Associated with Type 1 and Type 2 Diabetes, Europe, 2015
Figure 4 1: Onset, Peak and Duration of Insulin Types, Europe, 2015
Figure 4 2: Total Modern Insulin Market by Segment, Europe, 2012 – 2022 (€M)
Figure 4 3: Total Modern Insulin Market by Segment, Europe, 2012 – 2022 (US$M)
Figure 4 4: Total Modern Insulin Market, Europe, 2012 – 2022 (€ and US$)
Figure 4 5: Units Sold (Million mL) by Country, Total Modern Insulin Market, Europe, 2012-2022
Figure 4 6: Average Sales Price (per mL) by Country, Total Modern Insulin Market, Europe, 2012-2022 (€)
Figure 4 7: Average Sales Price (per mL) by Country, Total Modern Insulin Market, Europe, 2012-2022 (US$)
Figure 4 8: Total Modern Insulin Market by Country, Europe, 2012-2022 (€M)
Figure 4 9: Total Modern Insulin Market by Country, Europe, 2012-2022 (US$M)
Figure 4 10: Long-Acting Insulin Market, Europe, 2012 – 2022 (€ and US$)
Figure 4 11: Units Sold (Million mL) by Country, Long-Acting Insulin Market, Europe, 2012-2022
Figure 4 12: Average Sales Price (per mL) by Country, Long-Acting Insulin Market, Europe, 2012-2022 (€)
Figure 4 13: Average Sales Price (per mL) by Country, Long-Acting Insulin Market, Europe, 2012-2022 (US$)
Figure 4 14: Long-Acting Insulin Market by Country, Europe, 2012-2022 (€M)
Figure 4 15: Long-Acting Insulin Market by Country, Europe, 2012-2022 (US$M)
Figure 4 16: Rapid-Acting Insulin Market, Europe, 2012 – 2022 (€ and US$)
Figure 4 17: Units Sold (Million mL) by Country, Rapid-Acting Insulin Market, Europe, 2012-2022
Figure 4 18: Average Sales Price (per mL) by Country, Rapid-Acting Insulin Market, Europe, 2012-2022 (€)
Figure 4 19: Average Sales Price (per mL) by Country, Rapid-Acting Insulin Market, Europe, 2012-2022 (US$)
Figure 4 20: Rapid-Acting Insulin Market by Country, Europe, 2012-2022 (€M)
Figure 4 21: Rapid-Acting Insulin Market by Country, Europe, 2012-2022 (US$M)
Figure 4 22: Premixed Insulin Market, Europe, 2012 – 2022 (€ and US$)
Figure 4 23: Units Sold (Million mL) by Country, Premixed Insulin Market, Europe, 2012-2022
Figure 4 24: Average Sales Price (per mL) by Country, Premixed Insulin Market, Europe, 2012-2022 (€)
Figure 4 25: Average Sales Price (per mL) by Country, Premixed Insulin Market, Europe, 2012-2022 (US$)
Figure 4 26: Premixed Insulin Market by Country, Europe, 2012-2022 (€M)
Figure 4 27: Premixed Insulin Market by Country, Europe, 2012-2022 (US$M)
Figure 4 28: Drivers and Limiters, Insulin Market, Europe, 2015
Figure 4 29: Leading Competitors, Modern Insulin Market, Europe, 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report